An ideal strategy to treat both forms of AMD could potentially involve the use of current anti-VEGF therapy, together with inhibition of IL-1β and administration of recombinant IL-18 or potentiating the release of naturally occurring IL-18, possibly through an interference with IL-18BP. The gene discussed is IL18; the disease is age-related macular degeneration.